A vaccine against MERS has shown promise in mouse models, potentially aiding the development of a vaccine against COVID-19.
A new study suggests that a human recombinant soluble enzyme blocker, hrsACE2, significantly reduces SARS-CoV-2 viral load in human tissue, suggesting it could have the potential to prevent COVID-19.
Researchers from the University of Pittsburgh (PA, USA) have revealed the results from preclinical research testing their COVID-19 vaccine candidate in mice.
It’s a commonly known fact that the current global pandemic caused by the coronavirus originated in Wuhan, China. Over the first 50 days, a series of control measures were implemented to impede the spread, but were these measures effective?
There has been much contention regarding how the deadly COVID-19 pandemic originated. The first reported case of the disease was in Wuhan (Hubei province, China). The virus – SARS-CoV-2 – is believed to have been passed from animals to humans, but new data reveals pangolins could be linked to COVID-19 transmission.
Moderna has announced that the first participants have been dosed in a Phase I study of their mRNA candidate vaccine against SARS-CoV-2, the virus that causes COVID-19.
The first clinical trial assessing two triple artemisinin-based combination therapies (TACTs) for treating malaria has suggested these are effective and present no safety concerns.
Long-term follow-up of the ‘London patient’, the second patient to ever achieve sustained HIV remission after ceasing antiretroviral treatment, has suggested that there is no active detectable HIV virus remaining.
Upon investigating links between the risk of malaria in developing countries and the products demanded by consumers worldwide, researchers have estimated that a significant fraction of the malaria risk in deforestation hotspots is driven by the international trade of products.